Literature DB >> 12972176

Topiramate alters excitatory synaptic transmission in mouse hippocampus.

Jing Qian1, Jeffrey L Noebels.   

Abstract

Antiepileptic drugs may exert neuroprotective effects by decreasing excessive membrane excitability, neurotransmitter release, or postsynaptic Ca2+ entry. To assess these sites of action, we combined fluorescence Ca2+ imaging with extracellular field recording to analyze axonal excitability, evoked presynaptic Ca2+ entry through presynaptic Ca2+ channels, postsynaptic excitatory field potentials (fEPSP), and postsynaptic Ca2+ buildup ([Capost]) at the mouse hippocampal CA3-CA1 synapse exposed to topiramate (TPM). Topiramate had no effect on presynaptic Ca2+ entry, and produced only a minor inhibition of axonal excitability. Topiramate at concentrations up to 100 microM only slightly reduced the amplitude of the evoked fEPSP, but strongly inhibited the [Capost] evoked by repetitive synaptic activation. Postsynaptically, the action of TPM on the fEPSP and [Capost] was not mediated by an inhibition of the NMDA receptor, or by direct modulation of voltage-dependent Ca2+ channels, but reflected reduced somatic or dendritic membrane depolarization by AMPA and kainate receptors. These results are consistent with the known anticonvulsant properties of TPM. In addition, the ability of TPM to reduce postsynaptic Ca2+ buildup may provide a potential mechanism for neuronal protection during paroxysmal firing associated with epileptic seizures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972176     DOI: 10.1016/s0920-1211(03)00120-7

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  14 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 3.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.

Authors:  Robert B Raffa; Kristin E Finno; Christopher S Tallarida; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2010-09-19       Impact factor: 4.432

5.  Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Sulail Fatima; Tabassom Beiranvand; Shiva Mozaffari
Journal:  J Neural Transm (Vienna)       Date:  2017-08-09       Impact factor: 3.575

6.  Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3- exchange.

Authors:  Tobias Leniger; Jan Thöne; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

7.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

Review 8.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 9.  New generation anticonvulsants for the treatment of epilepsy in children.

Authors:  Elizabeth J Donner; O Carter Snead
Journal:  NeuroRx       Date:  2006-04

10.  Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.

Authors:  Steffen Naegel; Mark Obermann
Journal:  Neuropsychiatr Dis Treat       Date:  2010-02-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.